Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with investors Samsara BioCapital and Sheatree Capital. The company is developing a best-in-class logic-gate technology to spur a new generation of cell therapies for patients with solid tumors. Link’s “AND” gates require two cancer-associated targets for a CAR T cell to attack cancer cells, thereby providing specificity for killing of tumor cells while sparing healthy tissue. Combined with additional technologies under development, Link will advance a suite of exciting internal therapeutic programs while exploring opportunities for value creation with strategic partners.
Founded date: 2022
Investors 1
| Date | Name | Website |
| 09.08.2022 | MBC BioLab... | mbcbiolabs... |
Mentions in press and media 3
| Date | Title | Description |
| 15.12.2025 | Link Cell Therapies Raises $60M in Series A Financing | Link Cell Therapies, a San Francisco, CA-based oncology cell therapy company, raised $60M in Series A funding. The round was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation ... |
| 15.12.2025 | Link Cell Therapies Announces $60M Series A Financing | SOUTH SAN FRANCISCO, CA, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing. >> Click here for more funding data on Link Cell Therapies >> To ... |
| - | Link Cell Therapies | “Home - Link Cell Therapies” |